Germany continues to be a major focus for members of the international cannabis industry due to the exponential growth that the European nation’s domestic industry is experiencing. In just 2025 alone, Germany’s cannabis industry imported over 201 tonnes of medical cannabis products, up from 72.85 tonnes in 2024.

A wave of mergers and acquisitions has occurred in Germany, with the latest example being Curaleaf Holdings Inc., which has officially completed the full acquisition of Four 20 Pharma GmbH, a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis.

“The full acquisition of Four 20 Pharma strengthens Curaleaf’s vertically integrated, global supply chain, from owned cultivation sources in Portugal and Canada through to licensed distribution across Germany, delivering a true seed-to-patient quality guarantee and full oversight at every stage. Since the initial agreement in 2022, Curaleaf and Four 20 Pharma have collaborated closely to expand patient access, advance research initiatives, and streamline the international medical cannabis supply chain, validating a data-driven approach to education, cultivation, and product development.” the companies stated in a press release.

“Completing this buyout of the remaining stake in Four 20 Pharma reinforces our commitment to Europe and underscores the strategic importance of building high-quality, locally anchored operations in a market that will continue to grow exponentially,” said Boris Jordan, CEO and Chairman of Curaleaf. “Four 20 Pharma’s leadership in production, compliance, and distribution allows us to expand patient access to medical cannabis while driving innovation across the international market. This investment has been a meaningful, strategic anchor in our international strategy, and we’re looking forward to continued long-term growth in Europe.”

“Joining the Curaleaf family as a fully integrated subsidiary marks an exciting new chapter for Four 20 Pharma,” said Torsten Greif, Founder and Managing Director of Four 20 Pharma. “We built this company on an uncompromising commitment to quality, compliance, and patient care, values that align perfectly with Curaleaf’s international mission. Together, we are uniquely positioned to set the standard for medical cannabis across regulated markets worldwide.”

In addition to expanding operations in the legal German medical cannabis market, Curaleaf has also launched the Four 20 brand in both the United Kingdom and Poland. The company also has plans to continue expanding the brand across additional international markets.

Curaleaf Holdings, Inc. is a leading international provider of cannabis products with “a mission to enhance lives by cultivating, sharing and celebrating the power of the plant.” The company’s brands include Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem.

Additionally, Curaleaf International is powered by a strong presence in all stages of the supply chain with a unique distribution network throughout Europe, Canada, and Australasia, and a focus on pioneering science and research with cutting-edge cultivation, extraction, and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF.